[go: up one dir, main page]

AR047729A1 - Anticuerpos terapeuticos que se unen a la apolipoproteina e (apoe) - Google Patents

Anticuerpos terapeuticos que se unen a la apolipoproteina e (apoe)

Info

Publication number
AR047729A1
AR047729A1 ARP040104408A ARP040104408A AR047729A1 AR 047729 A1 AR047729 A1 AR 047729A1 AR P040104408 A ARP040104408 A AR P040104408A AR P040104408 A ARP040104408 A AR P040104408A AR 047729 A1 AR047729 A1 AR 047729A1
Authority
AR
Argentina
Prior art keywords
apoe
therapeutic antibodies
apolipoprotein
antibody
binds
Prior art date
Application number
ARP040104408A
Other languages
English (en)
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Publication of AR047729A1 publication Critical patent/AR047729A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/16—Central respiratory analeptics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Diabetes (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Psychology (AREA)
  • Communicable Diseases (AREA)
  • Emergency Medicine (AREA)
  • Virology (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Endocrinology (AREA)
  • Oncology (AREA)
  • Pulmonology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

Un anticuerpo o fragmento de anticuerpo humano, donde dicho anticuerpo o fragmento: i) se une a un polipéptido que tiene la secuencia de aminoácidos que se muestra en la SEQ ID No..: 1 del dominio C-terminal de la apolipoproteína E (ApocE-CTD) o la secuencia de aminoácidos de una parte de la misma; y ii) se une a placas humanas. Polinucleotidos, vectores que los comprenden, células huésped, así como composiciones farmacéuticas y su uso en métodos diagnostico de trastornos amiloides.
ARP040104408A 2003-11-28 2004-11-26 Anticuerpos terapeuticos que se unen a la apolipoproteina e (apoe) AR047729A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US52517403P 2003-11-28 2003-11-28

Publications (1)

Publication Number Publication Date
AR047729A1 true AR047729A1 (es) 2006-02-15

Family

ID=33564077

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP040104408A AR047729A1 (es) 2003-11-28 2004-11-26 Anticuerpos terapeuticos que se unen a la apolipoproteina e (apoe)

Country Status (16)

Country Link
US (1) US8058016B2 (es)
EP (2) EP2343318A3 (es)
JP (1) JP4869074B2 (es)
KR (2) KR20120108061A (es)
CN (1) CN1890266B (es)
AR (1) AR047729A1 (es)
AU (1) AU2004293180B2 (es)
BR (1) BRPI0417023A (es)
CA (1) CA2547675A1 (es)
GB (1) GB2408508A (es)
IL (1) IL175608A0 (es)
NO (1) NO20063026L (es)
RU (1) RU2006122946A (es)
TW (1) TW200530267A (es)
UY (1) UY28641A1 (es)
WO (1) WO2005051998A2 (es)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7658924B2 (en) 2001-10-11 2010-02-09 Amgen Inc. Angiopoietin-2 specific binding agents
EP2277532A1 (en) 2002-09-11 2011-01-26 Genentech, Inc. Novel composition and methods for the treatment of immune related diseases
DE10303974A1 (de) 2003-01-31 2004-08-05 Abbott Gmbh & Co. Kg Amyloid-β(1-42)-Oligomere, Verfahren zu deren Herstellung und deren Verwendung
WO2005058938A2 (en) 2003-12-15 2005-06-30 The Regents Of The University Of California Helical synthetic peptides that stimulate cellular cholesterol efflux
JP5475994B2 (ja) 2005-11-30 2014-04-16 アッヴィ・インコーポレイテッド 抗Ａβグロブロマー抗体、その抗原結合部分、対応するハイブリドーマ、核酸、ベクター、宿主細胞、前記抗体を作製する方法、前記抗体を含む組成物、前記抗体の使用及び前記抗体を使用する方法。
KR101439828B1 (ko) 2005-11-30 2014-09-17 애브비 인코포레이티드 아밀로이드 베타 단백질에 대한 모노클로날 항체 및 이의 용도
GB0621513D0 (en) * 2006-10-30 2006-12-06 Domantis Ltd Novel polypeptides and uses thereof
US8455626B2 (en) 2006-11-30 2013-06-04 Abbott Laboratories Aβ conformer selective anti-aβ globulomer monoclonal antibodies
PL2104682T3 (pl) * 2007-01-11 2017-03-31 Michael Bacher Diagnostyka i leczenie choroby Alzheimera i innych chorób neurodegeneracyjnych
WO2008104386A2 (en) 2007-02-27 2008-09-04 Abbott Gmbh & Co. Kg Method for the treatment of amyloidoses
IN2009DN05758A (es) 2007-03-12 2015-07-24 Esbatech Ag
NZ581468A (en) * 2007-06-25 2012-09-28 Esbatech Alcon Biomed Res Unit Methods of modifying antibodies, and modified antibodies with improved functional properties
RU2010102064A (ru) 2007-06-25 2011-07-27 Эсбатек, Эн Элкон Биомедикал Рисёрч Юнит Ллк (Ch) Способ конструирования, основанный на определении последовательностей, способ оптимизации одноцепочечных антител
WO2009033009A2 (en) * 2007-09-05 2009-03-12 Inotek Pharmaceuticals Corporation Antibodies against flagellin and uses thereof
JO2913B1 (en) 2008-02-20 2015-09-15 امجين إنك, Antibodies directed towards angiopoietin-1 and angiopoietin-2 proteins and their uses
HUE036780T2 (hu) 2008-04-09 2018-07-30 Genentech Inc Új kompozíciók és eljárások immunológiai vonatkozású betegségek kezelésére
ES2684475T3 (es) 2010-04-15 2018-10-03 Abbvie Inc. Proteínas que se unen a beta amiloide
EP3533803B1 (en) 2010-08-14 2021-10-27 AbbVie Inc. Anti-amyloid-beta antibodies
SG190952A1 (en) * 2010-12-02 2013-07-31 Univ Washington Compositions and methods for treating amyloid plaque associated symptoms
CN102863525B (zh) * 2011-07-04 2014-06-04 武汉大学 一种重组人apoE拟肽及制备方法和应用
KR20160030936A (ko) 2013-07-16 2016-03-21 제넨테크, 인크. Pd-1 축 결합 길항제 및 tigit 억제제를 사용한 암을 치료하는 방법
CN108137691B (zh) 2015-09-02 2021-10-19 耶路撒冷希伯来大学伊萨姆研究发展有限公司 特异性针对人类t-细胞免疫球蛋白和itim结构域(tigit)的抗体
NZ739750A (en) 2015-09-25 2019-11-29 Genentech Inc Anti-tigit antibodies and methods of use
LT3370768T (lt) 2015-11-03 2022-05-25 Janssen Biotech, Inc. Antikūnai, specifiškai surišantys pd-1, ir jų panaudojimas
CA3042236A1 (en) 2016-10-28 2018-05-03 Washington University Anti-apoe antibodies
US12398209B2 (en) 2018-01-22 2025-08-26 Janssen Biotech, Inc. Methods of treating cancers with antagonistic anti-PD-1 antibodies
EP3597222A1 (en) * 2018-07-16 2020-01-22 Easemedcontrol R & D GmbH & Co KG Treatment and diagnosis of unresolved inflammatory diseases
JP7686563B2 (ja) * 2019-02-08 2025-06-02 ルブリゾル アドバンスド マテリアルズ， インコーポレイテッド 皮膚、毛髪、爪および／または粘膜の処置および／またはケアに有用な化合物
WO2020176871A1 (en) * 2019-02-28 2020-09-03 Ann And Robert H. Lurie Children's Hospital Of Chicago Kawasaki disease antibodies identify hepacivirus peptides
EP3976642A4 (en) 2019-05-28 2023-11-08 The General Hospital Corporation Apoe antibodies, fusion proteins and uses thereof
EP3757121A1 (en) * 2019-06-28 2020-12-30 Eisai R&D Management Co., Ltd. Apolipoprotein e fragments
AU2021242326A1 (en) * 2020-03-27 2022-10-20 Epivax, Inc. Regulatory T cell epitopes
WO2025217042A2 (en) * 2024-04-09 2025-10-16 Absos, Llc Anti-b lymphocyte stimulator antibodies
WO2025217041A2 (en) * 2024-04-09 2025-10-16 Absos, Llc Anti-april antibodies

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1994009155A1 (en) * 1992-10-13 1994-04-28 Duke University Methods of detecting alzheimer's disease
US6107045A (en) 1994-06-30 2000-08-22 Oklahoma Medical Research Foundation Antibodies to lipoproteins and apolipoproteins and methods of use thereof
US5807978A (en) 1995-06-07 1998-09-15 Kokolus; William J. Immunogenic peptides of prostate specific antigen
US6046381A (en) 1998-04-30 2000-04-04 The Regents Of The University Of California Apolipoprotein E transgenic mice and assay methods
JP2002530122A (ja) * 1998-11-25 2002-09-17 サイオス インコーポレイテッド アミロイド関連疾患の予防及び治療
AU2002239766B9 (en) * 2000-11-03 2007-04-05 The J. David Gladstone Institutes Methods of treating disorders related to apoE
EP1368647A2 (en) * 2000-12-29 2003-12-10 Oxford GlycoSciences (UK) Limited Proteins, genes and their use for diagnosis and treatment of vascular response
WO2003031971A1 (fr) * 2001-10-04 2003-04-17 Immuno-Biological Laboratories Co., Ltd. Reactif pour detecter un facteur de risque de la maladie d'alzheimer, necessaire de detection a cet effet, et procede de detection du facteur de risque de la maladie d'alzheimer au moyen de ce necessaire
US7682795B2 (en) 2002-07-30 2010-03-23 The J. David Gladstone Institutes Method of diagnosing Alzheimer's Disease

Also Published As

Publication number Publication date
WO2005051998A3 (en) 2007-07-26
KR20060120161A (ko) 2006-11-24
NO20063026L (no) 2006-08-28
EP2343318A2 (en) 2011-07-13
GB0426043D0 (en) 2004-12-29
JP2008502311A (ja) 2008-01-31
US8058016B2 (en) 2011-11-15
AU2004293180B2 (en) 2011-09-15
US20100061993A1 (en) 2010-03-11
CN1890266B (zh) 2012-10-03
CN1890266A (zh) 2007-01-03
TW200530267A (en) 2005-09-16
EP2343318A3 (en) 2013-02-27
UY28641A1 (es) 2005-06-30
KR20120108061A (ko) 2012-10-04
BRPI0417023A (pt) 2007-02-21
AU2004293180A1 (en) 2005-06-09
GB2408508A (en) 2005-06-01
CA2547675A1 (en) 2005-06-09
RU2006122946A (ru) 2008-01-10
WO2005051998A2 (en) 2005-06-09
EP1687336A2 (en) 2006-08-09
JP4869074B2 (ja) 2012-02-01
IL175608A0 (en) 2006-09-05

Similar Documents

Publication Publication Date Title
AR047729A1 (es) Anticuerpos terapeuticos que se unen a la apolipoproteina e (apoe)
AR038568A1 (es) Anticuerpos anti-a beta y su uso
CY1118443T1 (el) Anti-tnf αντισωματα, συνθεσεις, μεθοδοι και χρησεις
CY1123400T1 (el) Ανθρωπινα anti-il-23 αντισωματα, συνθεσεις, μεθοδοι και χρησεις
AR080229A1 (es) Proteinas de dominio de armazon de fibronectina que se unen a il -23 (interleucina 23)
ATE497508T1 (de) Gegen das säugetier-eag1-ionenkanalprotein gerichtete antikörper
CO6180445A2 (es) Anticuerpos agonistas anti notch3 y su uso en el tratamiento de las enfermedades relacionadas con el gen notch3
RU2013110876A (ru) Активируемые биспецифические антитела
DE60032486D1 (de) Prion protein peptide und deren verwendung
GT200600182A (es) Anticuerpos dirigidos contra el peptido amiloide beta y metodo que utilizan los mismos
BRPI0713000A8 (pt) Proteína de ligação multiespecífica de cadeia simples, composição farmacêutica e uso da referida proteína de ligação multiespecífica de cadeia simples
AR033978A1 (es) Molecula de anticuerpo con especificidad para factor de necrosis tumoral alfa humano y usos de las mismas
AR046415A1 (es) Mimeticuerpos de nucleo de bisagra epo- mimeticos humanos, composiciones, metodos y usos
PE20050712A1 (es) Anticuerpos rg1
EA200601603A1 (ru) Миметические антитела glp-1 человека, композиции, способы и применения
EA201270517A1 (ru) Микобактериальные вакцины
PE20120532A1 (es) ANTICUERPOS ANTI-ActRIIB
EA200700136A1 (ru) Анти-cd154-антитела
BR0213303A (pt) Proteìnas de ligação de alvejamento direto
EA200001023A1 (ru) Специфическое в отношении fapa-(протеин альфа активации фибробласта) антитело с повышенной продуктивностью
AR064642A1 (es) Polinucleotido vector que lo comprende celula recombinante que comprende el vector polipeptido , anticuerpo , composicion que comprende el polinucleotido , vector , celula recombinante polipeptido o anticuerpo , uso de la composicion y metodo para preparar la composicion misma y preparar una composi
BRPI0606790A2 (pt) anticorpo humano isolado ou porção de ligação de antìgeno do mesmo, polipeptìdeo isolado, composição, ácido nucleico isolado, vetor de expressão célula hospedeira, vacina contra a raiva, kit, uso de um anticorpo monoclonal humano isolado ou porção de ligação de antìgeno do mesmo, ou de uma quantidade eficaz de uma composição, método para identificar um anticorpo ou um fragmento do mesmo, anticorpo ou fragmento do mesmo, anticorpo ou fragmento do mesmo,e, glicoproteìna.
AR079114A1 (es) Proteinas de enlace de antigenos anti-orai1 y usos de las mismas
EA201100072A1 (ru) Новые композиции и способы
ATE544780T1 (de) Hybrid-polypeptide mit eingefügten sequenzmotiven und ihre verwendungen

Legal Events

Date Code Title Description
FB Suspension of granting procedure